Affiliations 

  • 1 Centre for Health Economics, University of York, York, England, UK. Electronic address: [email protected]
  • 2 Institute for Clinical Effectiveness and Health Policy, Buenos Aires, Argentina
  • 3 Kalam Institute of Health Technology, Andhra Pradesh, India
  • 4 Institute for Clinical and Economic Review, Boston, MA, USA
  • 5 University of Utah, Salt Lake City, UT, USA; Monash University, Selangor, Malaysia; IDEAS Center, Veterans Affairs Salt Lake City Healthcare System, Salt Lake City, UT, USA
  • 6 Fudan University, Shanghai, China
  • 7 Ministry of Health, Mexico
  • 8 COEUS Consulting Group, Devon, PA, USA
  • 9 Ministry of Trade, Industry and Tourism, Colombia
  • 10 Canadian Agency for Drugs and Technologies in Health, Ottawa, Ontario, Canada
  • 11 Tufts Medical Center, Boston, MA, USA
  • 12 RTI Health Solutions, Ann Arbor, MI, USA
  • 13 Bocconi University, Milano, Italy
  • 14 Premera Blue Cross, Mountlake Terrace, WA, USA
  • 15 Kaiser Permanente Washington Health Research Centre, Seattle, WA, USA
Value Health, 2022 Aug;25(8):1257-1267.
PMID: 35931428 DOI: 10.1016/j.jval.2022.02.006

Abstract

Health technology assessment (HTA) has been growing in use over the past 40 years, especially in its impact on decisions regarding the reimbursement, adoption, and use of new drugs, devices, and procedures. In countries or jurisdictions with "pluralistic" healthcare systems, there are multiple payers or sectors, each of which could potentially benefit from HTA. Nevertheless, a single HTA, conducted centrally, may not meet the needs of these different actors, who may have different budgets, current standards of care, populations to serve, or decision-making processes. This article reports on the research conducted by an ISPOR Health Technology Assessment Council Working Group established to examine the specific challenges of conducting and using HTA in countries with pluralistic healthcare systems. The Group used its own knowledge and expertise, supplemented by a narrative literature review and survey of US payers, to identify existing challenges and any initiatives taken to address them. We recommend that countries with pluralistic healthcare systems establish a national focus for HTA, develop a uniform set of HTA methods guidelines, ensure that HTAs are produced in a timely fashion, facilitate the use of HTA in the local setting, and develop a framework to encourage transparency in HTA. These efforts can be enhanced by the development of good practice guidance from ISPOR or similar groups and increased training to facilitate local use of HTA.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.